# CORRESP — Black Diamond Therapeutics, Inc.  (BDTX)  (CIK 0001701541)

> <strong>Black Diamond Therapeutics, Inc.  (BDTX)  (CIK 0001701541) → SEC staff</strong> · filed 2025-12-01 · ticker BDTX · SIC 2836

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001104659-25-117310
- **Form:** CORRESP
- **Filer:** Black Diamond Therapeutics, Inc.  (BDTX)  (CIK 0001701541)
- **CIK:** 0001701541
- **Ticker:** BDTX
- **Filed:** 2025-12-01
- **SIC industry:** 2836
- **HQ:** Cambridge, MA

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1701541/000110465925117310/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1701541&type=UPLOAD&dateb=&owner=include&count=40

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, Black Diamond Therapeutics, Inc.  (BDTX)  (CIK 0001701541) (CIK 0001701541), filed 2025-12-01, accession 0001104659-25-117310. Retrieved via MORVS 2026-11-14 from https://api.morvs.ai/comment-letter/0001104659-25-117310.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*